|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM335244009 |
| 003 |
DE-627 |
| 005 |
20250302205934.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2022 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202106682
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1117.xml
|
| 035 |
|
|
|a (DE-627)NLM335244009
|
| 035 |
|
|
|a (NLM)34989039
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Lai, Xing
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Light-Triggered Efficient Sequential Drug Delivery of Biomimetic Nanosystem for Multimodal Chemo-, Antiangiogenic, and Anti-MDSC Therapy in Melanoma
|
| 264 |
|
1 |
|c 2022
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 31.03.2022
|
| 500 |
|
|
|a Date Revised 01.04.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2022 Wiley-VCH GmbH.
|
| 520 |
|
|
|a In view of the multiple pathological hallmarks of tumors, nanosystems for the sequential delivery of various drugs whose targets are separately located inside and outside tumor cells are desired for improved cancer therapy. However, current sequential delivery is mainly achieved through enzyme- or acid-dependent degradation of the nanocarrier, which would be influenced by the heterogeneous tumor microenvironment, and unloading efficiency of the drug acting on the target outside tumor cells is usually unsatisfactory. Here, a light-triggered sequential delivery strategy based on a liposomal formulation of doxorubicin (DOX)-loaded small-sized polymeric nanoparticles (DOX-NP) and free sunitinib in the aqueous cavity, is developed. The liposomal membrane is doped with photosensitizer porphyrin-phospholipid (PoP) and hybridized with red blood cell membrane to confer biomimetic features. Near-infrared light-induced membrane permeabilization triggers the "ultrafast" and "thorough" release of sunitinib (100% release in 5 min) for antiangiogenic therapy and also myeloid-derived suppressor cell (MDSC) inhibition to reverse the immunosuppressive tumor environment. Subsequently, the small-sized DOX-NP liberated from the liposomes is more easily uptaken by tumor cells for improved immunogenic chemotherapy. RNA sequencing and immune-related assay indicates therapeutic immune enhancement. This light-triggered sequential delivery strategy demonstrates the potency in cancer multimodal therapy against multiple targets in different spatial positions in tumor microenvironment
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a MDSC
|
| 650 |
|
4 |
|a biomimetic
|
| 650 |
|
4 |
|a multimodal therapy
|
| 650 |
|
4 |
|a near-infrared light
|
| 650 |
|
4 |
|a sequential drug delivery
|
| 650 |
|
7 |
|a Doxorubicin
|2 NLM
|
| 650 |
|
7 |
|a 80168379AG
|2 NLM
|
| 700 |
1 |
|
|a Liu, Xue-Liang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Pan, Hong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhu, Mao-Hua
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Long, Mei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yuan, Yihang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Zhong
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dong, Xiao
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lu, Qin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Sun, Peng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lovell, Jonathan F
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Hong-Zhuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Fang, Chao
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 34(2022), 10 vom: 07. März, Seite e2106682
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnas
|
| 773 |
1 |
8 |
|g volume:34
|g year:2022
|g number:10
|g day:07
|g month:03
|g pages:e2106682
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202106682
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 34
|j 2022
|e 10
|b 07
|c 03
|h e2106682
|